This follows last week’s post (Link) on the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies, based on the paper from Prof. Alexander Schuhmacher et al.
In that post I covered the author’s key takeaways on the overall impact of internal R&D, M&A, and in-licensing.
The data presented in this post are for individual companies, and provide a comparison of 14 of the top 20 companies by 2022 revenue.
The commentary is objective and not meant to say any particular expenditure or number of deals made is best, as there is vast amounts of context, and this study looks just at the output. It does not factor in the commercial success of any individual medicine.
Note: Use the arrows at the bottom of the PDF to scroll through the pages.
MA-Case-Study-2